Cargando…

Comparative Efficacy of Tegoprazan vs Esomeprazole/Sodium Bicarbonate for the Treatment of Helicobacter pylori Infection

INTRODUCTION: Potassium-competitive acid blockers and proton pump inhibitors/sodium bicarbonate can rapidly increase intragastric pH. In this study, we aimed to compare the clinical outcomes of tegoprazan-based and esomeprazole/sodium bicarbonate–based triple therapies in the treatment of Helicobact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Chan Hyuk, Park, Jung Ho, Jung, Yoon Suk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684139/ https://www.ncbi.nlm.nih.gov/pubmed/37561041 http://dx.doi.org/10.14309/ctg.0000000000000632

Ejemplares similares

Comparative Efficacy of 14-Day Tegoprazan-Based Triple vs. 10-Day Tegoprazan-Based Concomitant Therapy for Helicobacter pylori Eradication
por: Park, Chan Hyuk, et al.
Publicado: (2022)

Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study
por: Jung, Yoon Suk, et al.
Publicado: (2023)

Night‐time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2022)

Role of Tegoprazan in Helicobacter pylori Eradication Therapy
por: Lee, Jin
Publicado: (2022)

Efficacy of Tegoprazan for Improving the Susceptibility of Antimicrobial Agents against Antibiotic-Resistant Helicobacter pylori
por: Lee, Jung Won, et al.
Publicado: (2021)

Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
por: Lee, Kwang Jae, et al.
Publicado: (2019)

Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole
por: Yang, Eunsol, et al.
Publicado: (2023)

Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication
por: Kwon, Yong Hwan, et al.
Publicado: (2023)

The safety, pharmacodynamics, and pharmacokinetics of immediate-release formulation containing esomeprazole 20 mg/sodium bicarbonate 800 mg in healthy adult male
por: Kim, Dasohm, et al.
Publicado: (2019)

Dual Therapy Trial Using Esomeprazole and Amoxicillin as Third-line Rescue Therapy for Helicobacter pylori Infection
por: Park, Hyun Kyung, et al.
Publicado: (2011)

Effects of Tegoprazan Versus Esomeprazole on Nighttime Heartburn and Sleep Quality in Gastroesophageal Reflux Disease: A Multicenter Double-blind Randomized Controlled Trial
por: Kim, Joon Sung, et al.
Publicado: (2023)

Triple Therapy-Based on Tegoprazan, a New Potassium-Competitive Acid Blocker, for First-Line Treatment of Helicobacter pylori Infection: A Randomized, Double-Blind, Phase III, Clinical Trial
por: Choi, Yoon Jin, et al.
Publicado: (2022)

Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens
por: Shimoyama, Tadashi, et al.
Publicado: (2017)

Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin
por: Song, Zhiqiang, et al.
Publicado: (2019)

A Randomized, Double-Blind, Active-Control, Noninferiority, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of Esomeprazole/Sodium Bicarbonate 20/800 mg in Patients with Nonerosive Gastroesophageal Reflux Disease
por: Park, Su Hyun, et al.
Publicado: (2023)

Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes
por: Okimoto, Tadayoshi, et al.
Publicado: (2016)

Randomised clinical trial: comparison of tegoprazan and placebo in non‐erosive reflux disease
por: Kim, Seung Han, et al.
Publicado: (2021)

Efficacy of Tegoprazan in Patients with Laryngopharyngeal Reflux Disease: A Preliminary Feasibility Study
por: Jeon, Hye Kyung, et al.
Publicado: (2023)

Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers
por: Yoon, Deok Y., et al.
Publicado: (2021)

Efficacy and safety of high-dose esomeprazole–amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial
por: Bi, Hanxin, et al.
Publicado: (2022)

Tailored eradication strategy vs concomitant therapy for Helicobacter pylori eradication treatment in Korean patients
por: Choi, Youn I, et al.
Publicado: (2021)

Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese Population
por: Shih, Hsiang-Yao, et al.
Publicado: (2012)

High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication: a proof of concept study
por: Zullo, Angelo, et al.
Publicado: (2015)

The Sodium/Proline Transporter PutP of Helicobacter pylori
por: Rivera-Ordaz, Araceli, et al.
Publicado: (2013)

Dynamic Changes in Helicobacter pylori Status Following Gastric Cancer Surgery
por: Yoon, Kichul, et al.
Publicado: (2017)

Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis
por: Lee, Kang Nyeong, et al.
Publicado: (2022)

A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients with Helicobacter pylori infection
por: Mokhtare, Marjan, et al.
Publicado: (2020)

Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial
por: Suo, Baojun, et al.
Publicado: (2023)

Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch
por: Asghar, Waheed, et al.
Publicado: (2015)

Helicobacter pylori and Molecular Markers as Prognostic Indicators for Gastric Cancer in Korea
por: Kim, Hee Jin, et al.
Publicado: (2014)

Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease
por: Jeon, Hye Kyung, et al.
Publicado: (2022)

Different MicroRNA Expression Levels in Gastric Cancer Depending on Helicobacter pylori Infection
por: Chang, Hyun, et al.
Publicado: (2015)

Prevention and the treatment of oral mucositis: the efficacy of sodium bicarbonate vs other agents: a systematic review
por: Di Fede, O., et al.
Publicado: (2023)

Efficacy of sodium bicarbonate ingestion strategies for protecting blinding
por: Gurton, William H., et al.
Publicado: (2022)

The Effects of Helicobacter pylori Eradication Therapy for Chronic Idiopathic Thrombocytopenic Purpura
por: Hwang, Jae Jin, et al.
Publicado: (2016)

Developing Operational Definitions Related to Helicobacter pylori Eradication Therapy
por: Park, Chan Hyuk, et al.
Publicado: (2023)

Efficacy and safety of high-dose esomeprazole and amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori infection: a multicenter, randomized controlled clinical trial
por: Mei, Hao, et al.
Publicado: (2022)

Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis
por: Cho, Yu Kyung, et al.
Publicado: (2022)

Is Tegoprazan-Based Triple Therapy Effective in Regions with High Rates of Clarithromycin Resistance?
por: Choi, Hyun Ho
Publicado: (2023)

Changing Prevalence of Helicobacter pylori Infections in Korean Children with Recurrent Abdominal Pain
por: Jang, Kyung Mi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ffeghn9erj9h9bbppolo53rfr4